- Schaffer, Ashleigh E;
- Breuss, Martin W;
- Caglayan, Ahmet Okay;
- Al-Sanaa, Nouriya;
- Al-Abdulwahed, Hind Y;
- Kaymakçalan, Hande;
- Yılmaz, Cahide;
- Zaki, Maha S;
- Rosti, Rasim O;
- Copeland, Brett;
- Baek, Seung Tae;
- Musaev, Damir;
- Scott, Eric C;
- Ben-Omran, Tawfeg;
- Kariminejad, Ariana;
- Kayserili, Hulya;
- Mojahedi, Faezeh;
- Kara, Majdi;
- Cai, Na;
- Silhavy, Jennifer L;
- Elsharif, Seham;
- Fenercioglu, Elif;
- Barshop, Bruce A;
- Kara, Bulent;
- Wang, Rengang;
- Stanley, Valentina;
- James, Kiely N;
- Nachnani, Rahul;
- Kalur, Aneesha;
- Megahed, Hisham;
- Incecik, Faruk;
- Danda, Sumita;
- Alanay, Yasemin;
- Faqeih, Eissa;
- Melikishvili, Gia;
- Mansour, Lobna;
- Miller, Ian;
- Sukhudyan, Biayna;
- Chelly, Jamel;
- Dobyns, William B;
- Bilguvar, Kaya;
- Jamra, Rami Abou;
- Gunel, Murat;
- Gleeson, Joseph G
Neuronal migration defects, including pachygyria, are among the most severe developmental brain defects in humans. Here, we identify biallelic truncating mutations in CTNNA2, encoding αN-catenin, in patients with a distinct recessive form of pachygyria. CTNNA2 was expressed in human cerebral cortex, and its loss in neurons led to defects in neurite stability and migration. The αN-catenin paralog, αE-catenin, acts as a switch regulating the balance between β-catenin and Arp2/3 actin filament activities1. Loss of αN-catenin did not affect β-catenin signaling, but recombinant αN-catenin interacted with purified actin and repressed ARP2/3 actin-branching activity. The actin-binding domain of αN-catenin or ARP2/3 inhibitors rescued the neuronal phenotype associated with CTNNA2 loss, suggesting ARP2/3 de-repression as a potential disease mechanism. Our findings identify CTNNA2 as the first catenin family member with biallelic mutations in humans, causing a new pachygyria syndrome linked to actin regulation, and uncover a key factor involved in ARP2/3 repression in neurons.